Thank you for your submission to EMBO reports. We have now received the three enclosed reports on it, which can be found at the end of this email. As you will see, although all the referees find the topic of interest and in principle suitable for us, all of them also state that the study is preliminary for publication here at this stage. They request a number of technical improvements of the data and additional experiments that would be needed to provide convincing support for your study.
Thank you for your submission to EMBO reports. We have now received the three enclosed reports on it, which can be found at the end of this email. As you will see, although all the referees find the topic of interest and in principle suitable for us, all of them also state that the study is preliminary for publication here at this stage. They request a number of technical improvements of the data and additional experiments that would be needed to provide convincing support for your study.
Given that all referees provide constructive suggestions on how to make the work more conclusive, I would like to give you the opportunity to revise your manuscript. As the reports are pasted below, I will not summarize them in detail here. In this case, I find that it would be important to show: that SENP7 can de-SUMOylate KAP1 in vitro, provide cell cycle profiles of SENP7 knockdown cells, examine a single DSB when probing chromatin accesibility, perform rescue experiments with SENP7 catalytic and HP1-binding mutants, elucidate the stage of HR that is impaired upon SENP7 depletion, assess the changes in direct and indirect interactions after DNA damage (as requested by referee 3), as well as to perform all the controls, quantifications and additional validations requested by the referees. The three major points brought up by referee 2, however, are further reaching questions which could be out of the scope of a short report, and it would suffice to discuss them in the text.
I would like to point out that it is EMBO reports policy to allow a single round of revision and, thus, acceptance or rejection of the manuscript will depend on the outcome of the next, final round of peer-review. Please note that revised manuscripts must be submitted within three months of a request for revision unless previously discussed with the editor, as they will otherwise be treated as new submissions. I realize that addressing the referees comments in full would involve a lot of additional experimental work and I could potentially further extend this period, should you feel time would be the only limitation to a successful revision of the paper and depending on the state of the field.
Revised manuscript length must be a maximum of 30,000 characters (including spaces). When submitting your revised manuscript, please also include editable TIFF or EPS-formatted figure files, a separate PDF file of any Supplementary information (in its final format) and a letter detailing your responses to the referees.
We also welcome the submission of cover suggestions or motifs that might be used by our Graphics Illustrator in designing a cover.
I look forward to seeing a revised form of your manuscript when it is ready. In the meantime, do not hesitate to get in touch with me if I can be of any assistance.
REFEREE REPORTS:
Referee #1:
The manuscript submitted by Garvin et al. contends that the desumoylating enzyme, SENP7, is required for DNA double-strand break (DSB) repair by homologous recombination (HR). This is accomplished through an interaction with the chromatin-bound proteins KAP1 and HP1α. It is argued that SENP7 promotes the desumoylation of KAP1 in response to DNA damage which disrupts the recruitment of the chromatin remodeling complex, NuRD, through an interaction of the CHD3 subunit and SUMO2/3 conjugated to KAP1. The absence of the NuRD complex allows for the relaxation of heterochromatic regions that facilitates DSB repair.
Overall, the identification of SENP7 has a desumoylating enzyme in DSB repair is interesting. However, some of the key experiments lack controls or are poorly supported by the presented data, which dampened the Reviewer's enthusiasm for this paper.
Specific points
1-While the use of the DR-GFP system is a widely accepted means to monitor HR, the authors should also examine whether RAD51 focus formation is affected by SENP7 in an effort to provide additional validation of the role of SENP7 in HR-mediated DSB repair.
2-The authors need to present expression data for Figure 1C . In particular, is the C992A mutant expressed at similar levels to wild type SENP7? 3-On page 5, the authors indicate that SENP7 does not alter cell cycle position by referring to a study done in mouse cells (NIH 3T3; ref. 20) . It is conceivable that SENP7 knockdown in human cells could result in a different cell cycle profile and should be performed. Figure 2E that mutation of the NES, in the context of the mutation of the HP1-binding site, results in a SENP7 protein that is mainly nuclear. However, the primary data for this is lacking (i.e. in Figure S2D ) and should be included to better evaluate the quantitation. Figure 3C is a key experiment of the paper as it suggests that SENP7 depletion leads to a DNA damage-dependent increase in KAP1 sumoylation. This data seems supported by the extra band seen in Figure 3A in the C992. The quality of the gel/blot in Figure 3C is poor and since this should not be a difficult experiment (it is a Ni2+-NTA pulldown), it should be done again to at least give the reader confidence that the phenotype observed is robust.
4-The authors suggest in

5-
6-In parallel, I am curious about the extra band seen in the KAP1 immunoblots derived from cells expressing SENP7 C992A. Does this band correspond to sumoylated KAP1? 7-In the same vein, the authors should strengthen the data in Figure 3C by examining SENP7 mutants and whether the loss of SENP7-HP1 interaction results in hyper sumoylation of KAP1.
8-Can SENP7 de-sumoylate KAP1 in vitro? It would strengthen the model that SENP7 directly targets KAP1 for desumoylation.
9-The use of the EpiQ system to probe from chromatin accessibility after DNA damage is very interesting and is a welcome orthogonal approach to the MNase digestion experiment. However, it is not clear whether I-PpoI is the ideal system to look at the impact of SENP7 in the regulation of chromatin accessibility at the site of DNA damage. Indeed, I-PpoI cuts at many sites in the rDNA and the effects seen by the authors might not be related to changes in chromatin accessibility caused by the single euchromatin break mentioned. The data would be much stronger if they examined a single DSB (e.g. using I-SceI or a Zn2+ finger nuclease system); if they monitored multiple loci in the vicinity of the break site (or away from it) and finally, they should examine whether the "acute" DNA damage induced condensation seen in SENP7-depleted cells can be rescued by SENP7 catalytic and HP1-binding mutants.
Minor points 1. Figure 3D : the authors utilized 200 µg/ml of neocarzinostatin to induce DNA breaks. This is a massive amount of NCS, as most studies use between 100-200 ng/ml. Perhaps they meant 200 ng/ml? 2. Supp. Fig. 3C : no error bars for γH2AX foci quantification? The effect in chromocentres is quite small and it is not clear what the significance or relevance of this small effect is.
Referee #2:
Garvin et al., EMBO Reprots "The deSUMOylase SENP7 promotes chromatin relaxation for homologous recombination DNA repair" This manuscript has identified SENP7 plays an important role in homologous recombination (HR) and demonstrated that this role of SENP7 depends on its catalytic activity, its ability to bind SUMO2/3 conjugate, as well as its interaction with HP1a. It further proposes that KAP1 is a candidate substrate of SENP7, SENP7 regulates the level of polySUMO2/3 sumoylation of KAP1 which is important for mediating the interaction of KAP1 with the SIM domain-containing CHD3 thus regulates chromatin relaxation upon DNA damage. The manuscript also showed that CHD3 can rescue the defect of SENP7-deficient cells in HR and chromatin condensation upon DNA damage. The authors have proposed a new model to illustrate the role of deSUMOylation and the potential mechanism of SENP7 regulation on chromatin relaxation upon DNA damage.
There are several caveats in the proposed model: It has been reported that the SIM domain of CHD3 binds to SUMO1 modified KAP1 and phosphorylation of KAP1 perturbs the binding of CHD3-KAP1 releasing CHD3 for chromatin relaxation upon DNA damage. This manuscript showed that the same CHD3 SIM domain binds to polySUMO2/3 chain and suggested that SENP7 regulates polySUMO2/3 levels of KAP1 thus regulating the degree of KAP1-CHD3 interaction upon DNA damage. The authors need to reconcile their model with the previous model and clarify the choice of binding of the CHD3 SIM to either SUMO1 of SUMO2/3.
The authors propose that HP1a is required for binding of KAP1 to SENP. However, HP1a mostly localizes in the heterochromatin region, it is not clear whether the mechanism the authors proposed is a general mechanism for HR or specifically applied to HR in the heterochromatin region.
The authors showed that at least SIM6 and 7 of SENP7 is required for its function in HR. it is not clear whether SIM6 and 7 binds to polySUMO chains and how it is required for the function of SENP7 in regulating KAP1 interaction with CHD3.
Other comments: Figure 1 , the authors have investigated all six SENP enzymes and decided to focus on SENP7. Since the authors will not discuss the role of SENP6 in HR further, this review suggests the authors to move the SENP6 data to supplemental figures. Fig. 1B , it seems that the authors used siRNAs against SENP6 or SENP7 in cells overexpressing both SENP6 and SENP7 (correct?) . If this is the case, siSENP6 led to increased SUMO2/3 conjugates in the presence of overexpression of SENP7 (and similarly for SENP7), indicating SENP6 and SENP7 have non-overlapping targets. Thus, what is the effect of co-depletion of SENP6 and SENP7 in cell on HR repair?
Supplemental Fig.1F , the authors showed defects of SENP7 depleted cells in HR can be partially rescued by expressing of exogenous RFP-SUMO2/3. The authors indicate there is a "more specific role" for the SENP7 protease. The authors should further clarify that. What is the expression level of exogenous RFP-SUMO2/3? How efficient can it be conjugated to substrates relative to endogenous SUMO2/3? In Fig. 1C , the authors indicate that the role of SENP7 in HR largely depends on its catalytic activity, thus what is the "specific role" of SENP7 the authors are pointing to? Fig.2B , does SIM6 and 7 binds to polySUMO2 chains? Fig.2F , it appears that SIM-less SENP7 binds better to HP1a. Does SENP7 SIMs bind to sumoylated HP1a? Fig.2DandE , I guess the authors meant shaded box represents "cytoplasm and nucleus" Fig.2G , what about HP1m and NESm of SENP7 in chromatin fraction, for correlation with the HR rescue data presented in Fig.2H ? Fig.3A , the authors suggested that HP1 mediated binding of SENP7 and KAP1? Since only the catalytic C992A mutant of SENP7 binds to KAP1 robustly, the authors should test the NESm/HP1m/C992A mutant to test their hypothesis. Alternatively, test C992A interaction with KAP1 in HP1a depleted cells. Fig.3E , since the authors suggested that sumoylated KAP1 binds to CHD3 and is responsible for the increased retention of CHD3 on chromatin, they should include blots of KAP1 and SUMO2/3 sumoylated KAP1 in this assay. In the manuscript entitled "The deSUMOylase SENP7 promotes chromatin relaxation for homologous recombination DNA repair" Garvin et al. show that SENP7 interacts with the chromatin repressor KAP1 through HP1α, promoting the removal of SUMO2/3 from KAP1 and regulating the chromatin remodeler CHD3. They also show that SENP7 is required, in the presence of CHD3, for chromatin relaxation in response to DNA damage and homologous recombination repair. They conclude that deSUMOylation of KAP1 by SENP7 is required to promote a chromatin environment permissive for DNA repair. Overall, this manuscript addresses some important and topical issues. However, to make this work suitable for publication in EMBO Reports, I feel that the authors would have to successfully address the issues listed below.
General comments:
• It would be useful if the authors could demonstrate at what stage HR is impaired in SENP7 depleted cells, is it DNA end resection, RAD51 loading on resected DNA or some other step?
• Knock down efficiency of SENP 1,2,3 and 5 should be shown associated with the data presented in supplementary figure 1E.
• It has been previously reported (J Biol Chem. 2007 Dec 14; 282(50) :36177-89) that KAP1 SUMO modification is reduced following ATM dependent phosphorylation on S824. However, from figure 3A of the submitted manuscript one can conclude that at least the mono-SUMO KAP1 levels are not changed after DNA damage, while from figure 3C it appears that KAP1 SUMO modification is slightly induced by DNA damage and more so in SENP7 depleted cells. This leads me to question how SUMO-KAP1 suppresses HR, why the SUMO-KAP1 is induced by DNA damage even in the presence of SENP7 and how these data can be integrated into a coherent model? In this regard the addition of an illustration would help to deliver the conclusions reached by this manuscript.
• If the model suggests that by reducing the levels of SUMO modified KAP1 the affinity of CHD3 to KAP1 is reduced and this allows chromatin relaxation, wouldn't it be expected to detect reduction in SUMO modified KAP1 rather than an increase? • According to the proposed model one would expect to detect changes in the direct/indirect interactions following DNA damage between SENP7-HP1a-KAP1 and CHD3 and so wonder why is that not shown. In this regard the data provided is a very weak and suggesting that only in the absence of SENP7 an increased interaction between CHD3 peptide and KAP1 following NCS treatment is observed ( figure 3D ), could this be detected with recombinant and/or endogenous proteins and not just peptides?
• The authors should provide key control information to make their conclusions: o Although the authors cite a paper calming that SENP7 depletion does not result in significant changes in the cell cycle distribution, it is essential to show cell cycle distributions for SENP6 and SENP7 depletions as well as for the complementation with siRNA resistant SENP7 derivatives in this manuscript. o The expression levels of the SENP7 derivatives should also be shown. o HR assays throughout the manuscript should be accompanied and corrected to cell cycle distributions, as any changes to these could lead to indirect effects (including SENPs 1,2,3,5 in supplementary Fig 1E) .
Other issues:
• In supplementary figure 2D more cells should be shown and not just one. The scale bar on the lower right image is probably a mistake and should be fixed.
• Is the difference in HR mediated repair shown in supplementary figure 1C significant? Could this assay be repeated with depleting endogenous SUMO2? • For figure 1D , an associated immunoblotting showing gH2AX and other HR dependent signaling such as pSCHK1, pSRPA2 as well as the total levels of these proteins would significantly improve the data.
• The clonogenic survival assays shown in figure 1E would benefit from addition of positive controls such as CtIP depletion or other factors known to be required for HR mediated repair.
• In supplementary figure 1G, SENP7 depletion in the NHEJ assay should be added.
• In figure 2D and 2E what does the quantification refer to? Number of cells? • In figure 2D it seems that all cells (100%) have nuclear SENP7, while in supplementary figure 2E only about 65% have nuclear SENP7. Can the authors explain this?
• Figure 3D and 3E are of low quality and not very clear, they should ideally be improved. Additionally the conclusions drown from figure 3E with regards to CHD3 chromatin association/dissociation would be strengthened by showing it in an additional method such as immunofluorescence, FRAP and/or other methods.
• Figure 4D : is this clonogenic survival assay?
• Error bars throughout appear as only +. They should be presented in the + and -orientation.
• Why are the MNase digestion profiles of SENP7 in figures 4A and 4E so different? Referee #1:
The manuscript submitted by Garvin et al. contends that the desumoylating enzyme, SENP7, is required for DNA double-strand break (DSB) repair by homologous recombination (HR). This is accomplished through an interaction with the chromatin-bound proteins KAP1 and HP1α. It is argued that SENP7 promotes the desumoylation of KAP1 in response to DNA damage which disrupts the recruitment of the chromatin remodelling complex, NuRD, through an interaction of the CHD3 subunit and SUMO2/3 conjugated to KAP1. The absence of the NuRD complex allows for the relaxation of heterochromatic regions that facilitates DSB repair.
Specific points 1)-While the use of the DR-GFP system is a widely accepted means to monitor HR, the authors should also examine whether RAD51 focus formation is affected by SENP7 in an effort to provide additional validation of the role of SENP7 in HR-mediated DSB repair.
Reply:
We have examined RAD51 and now show SENP7 depletion abrogates the formation of RAD51 foci following both IR and CPT treatment (Fig 1) .
2-The authors need to present expression data for Figure 1C . In particular, is the C992A mutant expressed at similar levels to wild type SENP7?
Reply: The expression of WT versus C992A mutant of SENP7 is now included as a side panel. There is no difference in protein expression between these constructs (Fig 1) .
3-On page 5, the authors indicate that SENP7 does not alter cell cycle position by referring to a study done in mouse cells (NIH 3T3; ref. 20) . It is conceivable that SENP7 knockdown in human cells could result in a different cell cycle profile and should be performed.
The cell cycle distribution of SENP7 (and SENP6) depleted cells is now shown in (Supp Fig  1) . Depletion of SENP7 in human cells, like the murine Senp7 depletion does not affect cell cycle distribution. Figure 2E that mutation of the NES, in the context of the mutation of the HP1-binding site, results in a SENP7 protein that is mainly nuclear. However, the primary data for this is lacking (i.e. in Figure S2D ) and should be included to better evaluate the quantitation.
4-The authors suggest in
Reply: Primary data for this figure is now included in (Fig 2) . Figure 3C is a key experiment of the paper as it suggests that SENP7 depletion leads to a DNA damage-dependent increase in KAP1 sumoylation. This data seems supported by the extra band seen in Figure 3A in the C992. The quality of the gel/blot in Figure 3C is poor and since this should not be a difficult experiment (it is a Ni2+-NTA pulldown), it should be done again to at least give the reader confidence that the phenotype observed is robust.
5-
Reply: This has now been replaced, discrete bands moving up the gel are now resolved (Fig 3) .
6-In parallel, I am curious about the extra band seen in the KAP1 immunoblots derived from cells expressing SENP7 C992A. Does this band correspond to sumoylated KAP1? 7-In the same vein, the authors should strengthen the data in Figure 3C by examining SENP7 mutants and whether the loss of SENP7-HP1 interaction results in hyper sumoylation of KAP1. (Fig 3 and S3 ).
Reply:
We have now clarified our approach, which appears to have been misunderstood. The data in the figure was indeed carried out using the single cut site found with the DAB1 gene (expressed and euchromatic) and not the rDNA locus for the reasons stated by reviewer. We feel our rescue assays (of HR-repair, survival and chromatin relaxation) with CHD3 depletion are more informative than an attempt to rescue chromatin relaxation with SENP7 derivatives, (since we have already shown these do not rescue HR-repair of depleted cells). The CHD3 depletion rescue of SENP7 depletion links the remodelling to SENP7 activity, providing a relevant functional understanding of the pathway.
Minor points 1. Figure 3D : the authors utilized 200 µg/ml of neocarzinostatin to induce DNA breaks. This is a massive amount of NCS, as most studies use between 100-200 ng/ml. Perhaps they meant 200 ng/ml? Reply: This mistake has been corrected 2. Supp. Fig. 3C : no error bars for γH2AX foci quantification? The effect in chromocentres is quite small and it is not clear what the significance or relevance of this small effect is.
Reply: Error bars are now included, the differences are significant.
Referee #2:
Garvin et al., EMBO Reprots "The deSUMOylase SENP7 promotes chromatin relaxation for homologous recombination DNA repair"
This manuscript has identified SENP7 plays an important role in homologous recombination (HR) and demonstrated that this role of SENP7 depends on its catalytic activity, its ability to bind SUMO2/3 conjugate, as well as its interaction with HP1a. It further proposes that KAP1 is a candidate substrate of SENP7, SENP7 regulates the level of polySUMO2/3 sumoylation of KAP1 which is important for mediating the interaction of KAP1 with the SIM domain-containing CHD3 thus regulates chromatin relaxation upon DNA damage. The manuscript also showed that CHD3 can rescue the defect of SENP7-deficient cells in HR and chromatin condensation upon DNA damage.
The authors have proposed a new model to illustrate the role of deSUMOylation and the potential mechanism of SENP7 regulation on chromatin relaxation upon DNA damage.
There are several caveats in the proposed model:
It has been reported that the SIM domain of CHD3 binds to SUMO1 modified KAP1 and phosphorylation of KAP1 perturbs the binding of CHD3-KAP1 releasing CHD3 for chromatin relaxation upon DNA damage. This manuscript showed that the same CHD3 SIM domain binds to polySUMO2/3 chain and suggested that SENP7 regulates polySUMO2/3 levels of KAP1 thus regulating the degree of KAP1-CHD3 interaction upon DNA damage. The authors need to reconcile their model with the previous model and clarify the choice of binding of the CHD3 SIM to either SUMO1 of SUMO2/3.
Reply: Published evidence indicates KAP1 is SUMO1 modified but also SUMO2 modified ([1; 2]). The work of Goodarzi and others [3; 4] have utilised SUMO1 modified KAP1 for their studies, and did not examine SUMO2 binding. We have extended these studies and shown that the CHD3 SIM is also able to bind SUMO2 chains. We do not therefore envisage a choice in CHD3 binding to SUMO1 or SUMO2/3. Since SENP7 has clear proteolytic cleavage preference for SUMO2/3 isoforms, and undetectable activity against SUMO1 [5; 6] our data adds an additional layer of regulation indicating that the defence from SUMO modification has consequences for the regulation of KAP1-associations. A model clarifying this is now provided (Fig 4) .
Reply: Our data support the view that the mechanism is general since we are able to detect defects in both euchromatin, heterochromatin and also observe an impact on global chromatin state (Fig 4 and  S3) . We have clarified this point in the discussion and in the model.
We now provide evidence to indicate SIM 6 and 7 can bind polySUMO2 (fig 2) . Importantly the SIM-Less mutant is also able to interact with KAP1 (data not shown) indicating that it is unlikely SIM6 or SIM7 effect KAP1-CHD3 interaction directly, we speculate they are instead required for processing.
Other comments: 1) Figure 1 , the authors have investigated all six SENP enzymes and decided to focus on SENP7.
Since the authors will not discuss the role of SENP6 in HR further, this review suggests the authors to move the SENP6 data to supplemental figures.
Reply: We believe that for the initial experiments it is important to compare SENP6 and SENP7 side by side as to date no studies have been made comparing the in vivo activities of these Ulp2-related mammalian enzymes. Our data demonstrates that despite having similar substrate preferences their in vivo roles are quite different. The majority of the SENP6 data is within the supplemental data in order to support our focusing on SENP7.
2) Fig. 1B , it seems that the authors used siRNAs against SENP6 or SENP7 in cells overexpressing both SENP6 and SENP7 (correct?). If this is the case, siSENP6 led to increased SUMO2/3 conjugates in the presence of overexpression of SENP7 (and similarly for SENP7), indicating SENP6 and SENP7 have non-overlapping targets. Thus, what is the effect of co-depletion of SENP6 and SENP7 in cell on HR repair?
Reply: We apologise for the confusion, but these panels are for separate experiments and have now been separated to demonstrate the experiments more clearly. Fig 1B is to demonstrate the efficacy of SENP6 and SENP7 siRNA on exogenous Flag tagged constructs for each, and to show lack of cross effects of each siRNA. Fig 1C demonstrates the effect on SUMO2/3 conjugates following depletion of each SENP.
3) Supplemental Fig.1F , the authors showed defects of SENP7 depleted cells in HR can be partially rescued by expressing of exogenous RFP-SUMO2/3. The authors indicate there is a "more specific role" for the SENP7 protease. The authors should further clarify that. What is the expression level of exogenous RFP-SUMO2/3? How efficient can it be conjugated to substrates relative to endogenous SUMO2/3? In Fig. 1C , the authors indicate that the role of SENP7 in HR largely depends on its catalytic activity, thus what is the "specific role" of SENP7 the authors are pointing to?
Reply: This has been clarified in the figure legend. The data is gated on the RFP channel, so only SUMO2/3 expressing cells (or empty vector-expressing cells) are assessed for HR repair ability. RFP conjugated SUMO1/2/3 are efficiently conjugated to substrates as demonstrated by the numerous publications which have utilised them ([7; 8] ). The statement bearing the words 'specific role' has been changed to more accurately reflect the experimental results. Fig.2B , does SIM6 and 7 binds to polySUMO2 chains?
4)
Reply: We have included data (fig 2) showing that polySUMO2 chains bind to SENP7 fragments containing SIM6 and SIM7, while there is little/no binding to a mutant fragment in which both SIM motifs have been mutated. 5) Fig.2F , it appears that SIM-less SENP7 binds better to HP1a. Does SENP7 SIMs bind to sumoylated HP1a?
Reply: Agreed, a slight increase in HP1a immunoprecipitation is evident with the SIM-less mutant.
We also imagined at first that SENP7 may regulate HP1a-SUMOylation, however in our hands we have not observed SUMO2-modified HP1α in cells (for example using Ni2+ pull downs of His-SUMO2 modified proteins). From the data presented we can conclude that SENP7 association with HP1α is primarily mediated by the HP1/PxVxL motif in SENP7, more so than through SIM binding motifs. We speculate that SIM motifs are important in the processing of SUMO2-KAP1, although, it is feasible that the reduced interaction with SUMO through SIM-less somehow increases HP1 interaction. However, this is even further speculation (fig 3) . Reply: We have determined the localisation of these mutants (Fig 2) , further since the HP1m is entirely cytoplasmic we would assume it is not localised to the chromatin fraction. The NES mutant behaves as WT. 8) Fig.3A , the authors suggested that HP1 mediated binding of SENP7 and KAP1? Since only the catalytic C992A mutant of SENP7 binds to KAP1 robustly, the authors should test the NESm/HP1m/C992A mutant to test their hypothesis. Alternatively, test C992A interaction with KAP1 in HP1a depleted cells.
Reply: We thank the reviewer for this suggestion. To address this we mutated the catalytic site (C992A) in the NES/HP1m mutant of SENP7 and repeated the immunoprecipitation (fig 3) . This mutant was also unable to interact with KAP1, suggesting this interaction is indirect and mediated by the HP1 binding of SENP7 and indicating that the effect of the catalytic domain on SENP7:KAP1 interaction is secondary. 9) Fig.3E , since the authors suggested that sumoylated KAP1 binds to CHD3 and is responsible for the increased retention of CHD3 on chromatin, they should include blots of KAP1 and SUMO2/3 sumoylated KAP1 in this assay.
Reply:
We have included blots of KAP1; however the SUMO2/3 modified form of KAP1 is of relatively low abundance. To address this question more directly we have generated 4xSUMO2
fused to KAP1 to assess any role in retaining CHD3 (Fig 3) . These experiments show that polySUMO-KAP1 promotes the retention of CHD3 in the insoluble chromatin fraction. 10) Fig.4A , method reference for 4A and 4B?
Reply: The method for these figures can be found in (Supplemental Information, 4A is described under "Micrococcal nuclease digestion of chromatin (Analysis of chromatin structure)" and 4B under "Specific cut-site chromatin accessibility (EpiQ)".
Referee #3:
In the manuscript entitled "The deSUMOylase SENP7 promotes chromatin relaxation for homologous recombination DNA repair" Garvin et al. show that SENP7 interacts with the chromatin repressor KAP1 through HP1α, promoting the removal of SUMO2/3 from KAP1 and regulating the chromatin remodeler CHD3. They also show that SENP7 is required, in the presence of CHD3, for chromatin relaxation in response to DNA damage and homologous recombination repair. They conclude that deSUMOylation of KAP1 by SENP7 is required to promote a chromatin environment permissive for DNA repair. Overall, this manuscript addresses some important and topical issues. However, to make this work suitable for publication in EMBO Reports, I feel that the authors would have to successfully address the issues listed below.
General comments:
1) It would be useful if the authors could demonstrate at what stage HR is impaired in SENP7 depleted cells, is it DNA end resection, RAD51 loading on resected DNA or some other step?
Reply:. We have identified that RAD51 foci formation is lacking in SENP7 depleted cells, but that RPA foci are unaffected (fig1and Supp Fig 1) . Therefore the critical HR step of RAD51 loading/homology searching/strand invasion/ that is defective in cells lacking SENP7.
2) Knock down efficiency of SENP 1,2,3 and 5 should be shown associated with the data presented in supplementary figure 1E .
Reply: The knockdown efficiency of each SENP is shown in (Supp fig 1) .
3) It has been previously reported (J Biol Chem. 2007 Dec 14; 282(50) :36177-89) that KAP1 SUMO modification is reduced following ATM dependent phosphorylation on S824. However, from figure 3A of the submitted manuscript one can conclude that at least the mono-SUMO KAP1 levels are not changed after DNA damage, while from figure 3C it appears that KAP1 SUMO modification is slightly induced by DNA damage and more so in SENP7 depleted cells. This leads me to question how SUMO-KAP1 suppresses HR, why the SUMO-KAP1 is induced by DNA damage even in the presence of SENP7 and how these data can be integrated into a coherent model? In this regard the addition of an illustration would help to deliver the conclusions reached by this manuscript.
Reply: The exact nature of crosstalk between SUMO and ATM dependent phosphorylation of KAP1 is not completely understood and there are examples of contradictions in the literature e.g. refs: [3; 9] . Our data add weight to the findings that mono-SUMOylation is not altered on damage and that phosphorylation is not a bar to SUMO-modification. In addition, our data also show there is a mechanism of increased SUMOylation on DNA damage that is masked by the presence of SENP7. An illustration is now included to help deliver the conclusions (Fig 4) .
4) If the model suggests that by reducing the levels of SUMO modified KAP1 the affinity of CHD3 to KAP1 is reduced and this allows chromatin relaxation, wouldn't it be expected to detect reduction in SUMO modified KAP1 rather than an increase?
Reply: It is on SENP7 depletion that an increase in SUMO-KAP1 is detected, thus suggesting SENP7 acts to keep the levels of SUMO-KAP1 low. As stated at least one previous report [3] has not supported the view that SUMOylation is reduced on DNA damage. Our data adds weight to that conclusion, and consistent with it, we observed increased CHD3:chromatin interaction and decreased chromatin relaxation on depletion of the SUMO protease SENP7. An illustration is now included (Fig 4) .
5) According to the proposed model one would expect to detect changes in the direct/indirect interactions following DNA damage between SENP7-HP1a-KAP1 and CHD3 and so wonder why is that not shown? In this regard the data provided is a very weak and suggesting that only in the absence of SENP7 an increased interaction between CHD3 peptide and KAP1 following NCS treatment is observed ( figure 3D ), could this be detected with recombinant and/or endogenous proteins and not just peptides?
Reply: We have strengthened this section of the manuscript considerably with several additional experiments. We show that SENP7 depletion prevents the redistribution of a proportion of CHD3 from insoluble chromatin to the soluble nucleoplasm. Further we make the link with the influence of SENP7 on KAP1 by showing that KAP1-4xSUMO2-construct mimics the effect of SENP7 depletion, preventing the redistribution of CHD3.
6) Although the authors cite a paper calming that SENP7 depletion does not result in significant changes in the cell cycle distribution, it is essential to show cell cycle distributions for SENP6 and SENP7 depletions as well as for the complementation with siRNA resistant SENP7 derivatives in this manuscript.
We have now included cell cycle profiles of human SENP6 and SENP7 depleted cells (Supp fig 1) . As there are no effects of SENP7 siRNA on cell cycle distribution it is not necessary to perform these experiments for all the complementation assays.
7) The expression levels of the SENP7 derivatives should also be shown.
The expression of all SENP7 derivatives are now shown (Multiple figs).
8) HR assays throughout the manuscript should be accompanied and corrected to cell cycle distributions, as any changes to these could lead to indirect effects (including SENPs 1,2,3,5 in supplementary Fig 1E) .
Reply: As SENP7 depletion does not alter cell cycle profile HR assays do not need to be corrected to cell cycle distribution. We also measured RAD51 foci formation in cells counterstained with the late S and G2 marker CENPF and found SENP7 depletion results in loss of RAD51 foci. For individual SENPs, as we have focused on SENP6 and SENP7 in this short manuscript and have shown cell cycle profiles for these. We believe cell cycle profiles for the entire SENP family are unnecessary. We agree it is entirely likely that effects on cell cycle following SENP1/2/3/5 depletion are impacting HR/NHEJ repair indirectly. As such we have clarified in the text that these results reflect repair in a specific assay which may or may not be through direct effects.
9) In supplementary figure 2D more cells should be shown and not just one. The scale bar on the lower right image is probably a mistake and should be fixed.
Reply: Additional images with multiple cells are now shown in (fig 2) . 10) Is the difference in HR mediated repair shown in supplementary figure 1C significant? Could this assay be repeated with depleting endogenous SUMO2?
Reply: Yes the differences are significant. We would expect the differences to be more significant if endogenous SUMO2 was depleted from cells, although SUMO3 would also need to be depleted. The experiment in the supplemental figure provided us with the first indication that an activity related to processing SUMO2 is relevant to HR repair. We have then investigated this property more fully in the manuscript, resulting in our finding that SENP7 is significant in providing a permissive chromatin environment for HR repair. figure 1D , an associated immunoblotting showing gH2AX and other HR dependent signalling such as pSCHK1, pSRPA2 as well as the total levels of these proteins would significantly improve the data.
11) For
Reply:
We have improved the data by the examination of HR factors RPA and RAD51 (Supp Fig 1  and Fig 1) .
12) The clonogenic survival assays shown in figure 1E would benefit from addition of positive controls such as CtIP depletion or other factors known to be required for HR mediated repair.
Reply: BRCA2 depletion is now shown alongside control and SENP7 depletion as a point of reference (Fig 2) .
13) In supplementary figure 1G, SENP7 depletion in the NHEJ assay should be added.
Reply: As SENP7 depletion does not alter NHEJ (Fig 1) repair these assays were not performed.
14) In figure 2D and 2E what does the quantification refer to? Number of cells?
Reply: Quantification and cell number are described in the figure legend.
15) In figure 2D it seems that all cells (100%) have nuclear SENP7, while in supplementary figure 2E only about 65% have nuclear SENP7. Can the authors explain this?
Reply: The discrepancy is due to Flag-SENP7 expression being entirely nuclear, while endogenous SENP7 (as detected by two different SENP7 antibodies derived from different epitopes) detects nuclear and some cytoplasmic localisation. This may be due to cytoplasmic isoforms of SENP7 or non specific protein detected by the antibodies. As such we are unable to describe endogenous SENP7 as being 100% nuclear.
15) Figure 3D and 3E are of low quality and not very clear, they should ideally be improved. Additionally the conclusions drown from figure 3E with regards to CHD3 chromatin association/dissociation would be strengthened by showing it in an additional method such as immunofluorescence, FRAP and/or other methods.
We have now provided further evidence to demonstrate the role of SENP7 on CHD3:chromatin distribution showing that SENP7 depletion prevents the redistribution of a proportion of CHD3 from insoluble chromatin to the soluble nucleoplasm. Figure 4D : is this clonogenic survival assay?
16)
Reply: Yes.
17) Error bars throughout appear as only +. They should be presented in the + and -orientation.
Reply: All error bars are now in the -/+ orientation.
18) Why are the MNase digestion profiles of SENP7 in figures 4A and 4E so different?
Reply: This is due to differences in the axis scales between panels, they have now been harmonised. Thank you for your patience while your revised study has been under peer-review. It was sent to referees 1 and 3 of the previous version. As you will see, referee 3 has numerous outstanding serious concerns that preclude the publication of your study here. As I mentioned in my previous decision letter, this round of peer-review would be final.
As our standard procedure, we consulted with both referees before making a final decision. Referee 1, although acknowledging the amount of work done during revision, noted that the outstanding concerns were indeed critical, especially number 3. S/he emphasized the inconsistencies between your model, your data and the literature, and thought this is not an easily addressable issue. We have thus decided to decline the publication of your study at this stage.
I am sorry to disappoint you on this occasion, hope that the referee comments are helpful in your continued work in this area and that you soon receive a more favorable response elsewhere.
REFEREE REPORTS:
The authors have made significant improvements on their manuscript and they have adequately addressed my comments.
In the new version of the manuscript entitled "The deSUMOylase SENP7 promotes chromatin relaxation for homologous recombination DNA repair" by Garvin et al. the authors have successfully addressed some of my comments but fail to address a substantial proportion of my essential comments to the initial submission. In light of these issues, I hence cannot recommend it for publication in EMBO Reports, at least in its current state. Please see below assessment of the author's reply/rebuttal in which I address only those issues that have not been adequately resolved. Fig 1) . Therefore the critical HR step of RAD51 loading/homology searching/strand invasion/ that is defective in cells lacking SENP7.
Reviewer's comment: Pinpointing the HR defect in SENP7 depleted cells to RAD51 loading is a welcome addition to the story. However this reviewer finds it difficult to understand how the absence of chromatin relaxation, which is needed for HR, will allow efficient DNA end resection and RPA loading but will only impair the crucial step of replacing RPA with RAD51 on resected DNA. Can the authors either explain or somehow address this issue? Additionally, it would be best when marking the cell cycle stage while analyzing RAD51 and RPA (Fig 1F and S1I ) not to exclude S-phase cells as done by the authors by using CENPF which they state marks G2 cells (or late S and G2). An alternative is to use CyclinA that is detectable in both S and G2 cells. In Fig S1I, more cells should be shown and the RPA and CENPF channels should be separated in order to properly assess the authors' conclusion that RPA foci are intact in SENP7 depleted cells. In Fig 1F , as RAD51 levels are not known to be cell cycle regulated, one would expect all cells to show RAD51 and RAD51 foci only in cells undergoing HR mediated repair, so where is RAD51 in all the other control cells and in all SENP7 and BRCA2 depleted cells? These issues must be adequately resolved.
3) It has been previously reported (J Biol Chem. 2007 Dec 14;282(50):36177-89) that KAP1 SUMO modification is reduced following ATM dependent phosphorylation on S824. However, from figure  3A of the submitted manuscript one can conclude that at least the mono-SUMO KAP1 levels are not changed after DNA damage, while from figure 3C it appears that KAP1 SUMO modification is slightly induced by DNA damage and more so in SENP7 depleted cells. This leads me to question how SUMOKAP1 suppresses HR, why the SUMO-KAP1 is induced by DNA damage even in the presence of SENP7 and how these data can be integrated into a coherent model? In this regard the addition of an illustration would help to deliver the conclusions reached by this manuscript.
Reply: The exact nature of crosstalk between SUMO and ATM dependent phosphorylation of KAP1 is not completely understood and there are examples of contradictions in the literature e.g. refs: [3; 9]. Our data add weight to the findings that mono-SUMOylation is not altered on damage and that phosphorylation is not a bar to SUMO-modification. In addition, our data also show there is a mechanism of increased SUMOylation on DNA damage that is masked by the presence of SENP7. An illustration is now included to help deliver the conclusions (Fig 4).
Reviewer's comment: I do not think that my previous comments have been adequately addressed:
The authors state that KAP1S824 is not a bar to its SUMO modification but in their model there is an inhibitory mark from KAP1pS824 to the SUMO modification, these are not consistent. In this regard will KAP1 S824A show differences in its SUMO modification while non SUMOlatable KAP1will be phosphorylated as the WT KAP1? Will these mutations affect the CHD3 interaction and HR? Additionally, according to the authors' model a reduction in KAP1 SUMO modification promoted by SENP7 should be detected in control cells as this is needed for release of CHD3, chromatin relaxation and proper HR that is progressing normally in those cells, why is that not detected? Paradoxically the authors claim that there is actually induction of KAP1 SUMO modification that is masked by the presence of SENP7 and is clearly detected in its absence; this would argue against their model of reduction in the KAP1-SUMO modified forms to allow release of CHD3 and subsequent chromatin relaxation and efficient replacement off RPA with RAD51. While efficient DNA end resection and RPA loading occur efficiently in the absence of SENP7, only the RPA-RAD51 replacement appears to be impaired. To us these observations do not tie up.
My previous comment number 4 also tries to address the above-mentioned apparent discrepancies and still stands as the authors have failed to adequately explain them.
5) According to the proposed model one would expect to detect changes in the direct/indirect interactions following DNA damage between SENP7-HP1a-KAP1 and CHD3 and so wonder why is that not shown? In this regard the data provided is a very weak and suggesting that only in the absence of SENP7 an increased interaction between CHD3 peptide and KAP1 following NCS treatment is observed ( figure 3D ), could this be detected with recombinant and/or endogenous proteins and not just peptides? Reviewer's comment: The authors' additional experiments regarding CHD3 chromatin association in a SUMO-fused KAP1 are indeed informative, however they do not address the points previously raised.
Reply: We have now included cell cycle profiles of human SENP6 and SENP7 depleted cells (Supp fig1). As there are no effects of SENP7 siRNA on cell cycle distribution it is not necessary to perform these experiments for all the complementation assays.
Reviewer's comment: The cell cycle profiles for SENP6 and SENP7 that are shown only include numbers representing the proportions of cells in G2. For a proper assessment of the effect of the cell cycle distribution on HR mediated DSB repair, the proportion of cells in S and G2 should be evaluated.
8) HR assays throughout the manuscript should be accompanied and corrected to cell cycle distributions, as any changes to these could lead to indirect effects (including SENPs 1,2,3,5 in supplementary Fig 1E) . Reviewer's comment: As mentioned above, cell cycle profiles relevant to HR mediated repair should be correlated to the proportion of cells in S and G2 and not just G2. CENPF marks cells in G2 as the authors state in Fig 1H and as far as we are aware HR mediated repair is active in S and G2 and is not restricted to late S and G2. Additionally, I have concerns about the RAD51 staining as shown in Fig 1H ( see the end of comment to point number 1). figure 1D , an associated immunoblotting showing gH2AX and other HR dependent signaling such as pSCHK1, pSRPA2 as well as the total levels of these proteins would significantly improve the data. Fig 1  and Fig 1) .
Reply
11) For
Reply: We have improved the data by the examination of HR factors RPA and RAD51 (Supp
Reviewer's comment: My previous comment was not addressed even though it should be relatively simple and only require whole cell extracts treated with CPT or not to be analyzed by immunoblotting.
The affect of SENP7 in de-sumoylating SUMO-KAP1 shown in Fig 3E is not very convincing.
Correspondence -authors' response -appeal 24 July 2013
Many thanks for your email. Following the description of the review process you provided and reading the reviewer 3s response I would like to strongly request that the manuscript is viewed by a further reviewer.
Our reasons are as follows:
First -Ref 3's comparison to the JBC paper:
1) This paper was on SUMO1 only, ours is on SUMO2 only therefore direct comparisons between two different modifications are not meaningful.
2) The findings of this paper (regarding mutual exclusivity of SUMO1 and phospho) are directly contradicted by a subsequent paper (NSMB, Goodarzi et al 2011).
Therefore we are in an impossible position: we cannot completely agree with the literature as the literature is contradictory. We note however that on balance we are being criticised for not agreeing with a paper (JBC 2007) on a different modification which has already been contradicted by another publication. Ref 3 never concedes that some of the findings of the JBC 2007 paper have been contradicted, thus either they are unaware of this or not an unbiased reviewer. Certainly one reading of their comments is that they are unwilling to accept any model other then the JBC 2007 story.
Second: All other views expressed by Ref 3 are either new to the review, i.e they ask for further questions to be addressed that were not put in the first review, are erroneous (no issue exists), have actually been addressed (for example cell cycle analysis), or have been superseded by new data. I provide a reasoned response below to each of these.
I hope with a view to a fair review process you are able to send this out once more.
----------Rebuttal comments:
In the new version of the manuscript entitled "The deSUMOylase SENP7 promotes chromatin relaxation for homologous recombination DNA repair" by Garvin et al. the authors have successfully addressed some of my comments but fail to address a substantial proportion of my essential comments to the initial submission. In light of these issues, I hence cannot recommend it for publication in EMBO Reports, at least in its current state. Please see below assessment of the author's reply/rebuttal in which I address only those issues that have not been adequately resolved.
Reviewer's comment: Pinpointing the HR defect in SENP7 depleted cells to RAD51 loading is a welcome addition to the story. However this reviewer finds it difficult to understand how the absence of chromatin relaxation, which is needed for HR, will allow efficient DNA end resection and RPA loading but will only impair the crucial step of replacing RPA with RAD51 on resected DNA. Can the authors either explain or somehow address this issue? Additionally, it would be best when marking the cell cycle stage while analyzing RAD51 and RPA (Fig 1F and S1I ) not to exclude S-phase cells as done by the authors by using CENPF which they state marks G2 cells (or late S and G2). An alternative is to use CyclinA that is detectable in both S and G2 cells. In Fig S1I, more cells should be shown and the RPA and CENPF channels should be separated in order to properly assess the authors' conclusion that RPA foci are intact in SENP7 depleted cells. In Fig 1F, as RAD51 levels are not known to be cell cycle regulated, one would expect all cells to show RAD51 and RAD51 foci only in cells undergoing HR mediated repair, so where is RAD51 in all the other control cells and in all SENP7 and BRCA2 depleted cells? These issues must be adequately resolved.
We have addressed the original question and shown RAD51 foci are defective whereas RPA are not. This reviewer now posses a second question -that of "how?" This is indeed an interesting question but beyond the scope of a report describing a novel finding of the impact of SENP7 polySUMOylation on chromatin, required for HR. This interesting point is addressed in the discussion (where we note that others have also seen this as the break-point in heterochromatin, due to the word limit only one reference is given, in addition we could have also referred to: J Cell Biol. 2012 Dec 24;199(7):1067-81" The chromatin remodeler p400 ATPase facilitates Rad51-mediated repair of DNA double-strand breaks ). I don't understand the objection of using CENPF over Cyclin A. CENPF marks late S phase and G2. HR occurs in late S phase and G2 (not early S-phase). Thus it is entirely an appropriate marker. We use both markers in the lab routinely in this experiment there is no likelihood that the results of one marker over the other would be any different. We note that data without a cell cycle marker also shows reduced RAD51 foci. The effect is so dramatic that any or no cell cycle marker shows the same thing. The remainder of the points are very minor -we have merged colour channels for reasons of space -and can separate them happily. I have read the RAD51 sentence many times and do not understand what the objection is. Yes indeed RAD51 is not cell cycle regulated and yes we'd expect to see it at the protein level in all cells, but on as foci in HR-proficient cells. This is what we see. RAD51 is present at the protein level in BRCA2 and SENP7 depleted cells, but as expected not present in foci. We showed RAD51 presence in a western blot to counter any possibility that its absence in foci in SENP7 depleted cells is due to some off target effect on RAD51 protein levels. I can see no issue to resolve here.
Reply: The exact nature of crosstalk between SUMO and ATM dependent phosphorylation of KAP1 is not completely understood and there are examples of contradictions in the literature e.g. refs: [3; 9]. Our data add weight to the findings that mono-SUMOylation is not altered on damage and that phosphorylation is not a bar to SUMO-modification. In addition, our data also show there is a mechanism of increased SUMOylation on DNA damage that is masked by the presence of SENP7. An illustration is now included to help deliver the conclusions (Fig 4).
There is considerable misunderstanding here. We have not shown, do not claim, and have not given the impression that SUMO1-modification of KAP1 is regulated by SENP7. This maybe what this review thinks our manuscript is about. Further the reviewer's comments refer to the JBC 2007 paper findings but do not take into account that of the NSMB 2011 paper (Goodarzi et al). The NSMB paper also makes the point that phosphorylation is no bar to SUMO1 modification. Our model does not show an inhibitory mark, but describes the findings of the 2011 NSMB paper; that there is competition of phosphoKAP1-for SUMO1-KAP1 thereby preventing CHD3 interaction with KAP1-SUMO1 (as the reviewer appears to understand in later comments).
It is not the case that 'according to our model' 'a reduction in KAP1 SUMOylation would be expected in control cells'. Our data show SENP7 constitutively prevents excessive SUMO2ylation of KAP1. It does not prevent SUMO1 modification (it has no activity to SUMO1), further our in vitro data indicate it has no activity to mono-SUMO2. Our data confirms previous extensive biochemical studies indicating SENP7 is a chain-editing protease. We show that SENP7 is constitutively associated with KAP1, constitutively preventing over-SUMO2/3 modification. Thus only in the absence of SENP7 would one expect increased KAP1 SUMO2ylation and increased CHD3:chromatin association and impact on chromatin and impact on HR (as we observe). Efficient end resection, but a failure of RPA-RAD51 entirely 'fit's with our model that SENP7 restricts polySUMO2ylation of KAP1.
We have done our best within the word limit to address inconsistencies of the literature and to bring the details of our model to life. Importantly our data is internally consistent and largely builds on the data of the 2011 NSMB paper.
The reviewer and editor asked for direct indirect interactions on DNA damage. To directly address the impact of SUMO2-KAP1 on CHD3 association with chromatin we performed what was a more informative experiment -making polySUMO-KAP1 -directly answering the DNA-damaging dependent association of CHD3. We accept that we didn't do this experiment in the way the reviewer asked, considering that over-expression interactions as suggested would not add to further strength to the data already shown using peptides. We note our data that polySUMO-fused-KAP1 increases CHD3 association with chromatin is consistent with our other finding and our proposed model. 6) Although the authors cite a paper calming that SENP7 depletion does not result in significant changes in the cell cycle distribution, it is essential to show cell cycle distributions for SENP6 and SENP7 depletions as well as for the complementation with siRNA resistant SENP7 derivatives in this manuscript. Reviewer's comment: The cell cycle profiles for SENP6 and SENP7 that are shown only include numbers representing the proportions of cells in G2. For a proper assessment of the effect of the cell cycle distribution on HR mediated DSB repair, the proportion of cells in S and G2 should be evaluated.
Reply
The proportion shown in G2 to illustrate the data and to not over-fill the image with numbers that are already obvious from the cycle profiles -that there is no impact of SENP7 depletion on G1, S or G2.
8) HR assays throughout the manuscript should be accompanied and corrected to cell cycle distributions, as any changes to these could lead to indirect effects (including SENPs 1,2,3,5 in supplementary Fig 1E) . Reviewer's comment: As mentioned above, cell cycle profiles relevant to HR mediated repair should be correlated to the proportion of cells in S and G2 and not just G2. CENPF marks cells in G2 as the authors state in Fig 1H and as far as we are aware HR mediated repair is active in S and G2 and is not restricted to late S and G2. Additionally, I have concerns about the RAD51 staining as shown in Fig 1H (see the end of comment to point number 1).
The proportion shown in G2 to illustrate the data and to not over-fill the image with numbers that are already clear from the cycle profiles (as well as previously shown for murine SENP7 which we have illustrated has a conserved role in DNA repair). CENPF marks late S phase and G2. HR occurs in late S phase and G2 (not early S-phase). It is entirely an appropriate marker, used by may other researchers in this field. figure 1D , an associated immunoblotting showing gH2AX and other HR dependent signaling such as pSCHK1, pSRPA2 as well as the total levels of these proteins would significantly improve the data. Fig 1  and Fig 1) .
11) For
Reply: We have improved the data by the examination of HR factors RPA and RAD51 (Supp
Our paper already occupies considerably more panels than an EMBO R manuscript is expected to. Since the RPA and RAD51 (and 53BP1 and BRCA1) data added in review contribute more to the story that the requested immunoblot we did not show the immunoblot, considering the added detail of was more meaningful. The immunoblot has been done, but what it brings to a complete story and busy paper is not clear.
Unlike almost all previous reports on KAP1 we have examined the impact on endogenous protein by depleting the endogenous SENP7. I'm sure a more 'convincing' blot could be generated with overexpression studies. In addition to the impact on endogenous KAP1 we have shown SENP7 deSUMOylates polySUMO2-KAP1 in vitro. We are interested in what actually happens in cells and our data strongly supports the view that the impact of SENP7 on KAP1-SUMOylation status (restricting polySUMOylation) is physiologically significant: we have shown polySUMO-KAP1 offers a phenocopy the CHD3-retention induced by SENP7 depletion. We have shown CHD3 restricts chromatin, HR and cell survival in the absence of SENP7.
Correspondence -editor 25 July 2013
I appreciate your frustration with the outcome of the process. Unfortunately, the remaining referee concerns have in essence already been seen by another reviewer, namely referee 1. Both are trusted referees, and especially referee 1, knows the journal well.
Upon further consultation with this referee, s/he highlighted also the inconsistencies between the model and the data provided, as well as (but not only) with the literature. Nevertheless, I would be happy to send your letter addressing the referee concerns to referee 1 seeking his/her further input. We will not, however, at this stage, involve an additional reviewer. I trust this is a reasonable course of action and will be back in touch as soon as possible with a decision on your study that will be final.
Correspondence -authors' reply 25 July 2013
Many thanks for your quick reply. Yes I would be happy for this to proceed as you suggest.
3rd Editorial Decision 26 July 2013
I have now had time to assess your responses to the remaining concerns of referee 3, as well as to receive further input from referee 1. We both appreciate your arguments and consider that the study is suitable for publication in EMBO reports after minor revision.
Regarding the outstanding concerns, I would ask you to perhaps discuss your model and the literature in more detail, as future readers might be confused, as was referee 3 (and also initially referee 1). In this regard, the legend to figure 4G will also have to be more informative and not simply refer to supplementary material for explanations.
In addition, please modify Fig. 1F to show each channel independently and show more cells in Fig S1I . It would also be good to cite the JCB study on p400 facilitating Rad51 repair, and in the introduction mention that there are two other families of SUMO proteases (it now reads like only SENPS cleave SUMO)-incidentally both published in EMBO reports last year, studies which seems appropriate to cite.
I have also realized that the materials and methods section is extremely succinct. It is EMBO reports policy that basic Materials and Methods required for understanding the experiments performed must remain in the main text, although additional detailed information may be included as Supplementary Material.
Shortening to accommodate all of these changes may be made easier by combining the Results and Discussion into a single section, which we require, and which will help eliminate the redundancy that is inevitable when discussing the same experiments twice. Also, if necessary, I could potentially increase the length to a maximum of 34,000 characters, given that four figures instead of five.
The information on the number of experiments performed, identity of the error bars and statistical analyses (where applicable) seems rather inconsistently included. Please ensure that all relevant figures and supplementary figure legends include this information. If most figures are based on a common number of experiments and the data have been analyzed similarly, you may include a paragraph in the Methods section explaining the analyses performed and only provide specific information in the legends of the cases that deviate from the general procedure.
As a standard procedure, we edit the title and abstract of manuscripts to make them more accessible to a general readership. In this case, I have not modified the title, but please find the edited abstract at the end of this email and let me know if you do NOT agree with any of the changes.
Finally, we now encourage the publication of original source data -particularly for electrophoretic gels and blots, but also for graphs-with the aim of making primary data more accessible and transparent to the reader. If you agree, you would need to provide one PDF file per figure that contains the original, uncropped and unprocessed scans of all or key gels used in the figures and an Excel sheet or similar with the data behind the graphs. The files should be labeled with the appropriate figure/panel number, and the gels should have molecular weight markers; further annotation could be useful but is not essential. The source files will be published online with the article as supplementary "Source Data" files and should be uploaded when you submit your final version. If you have any questions regarding this please let us know.
I look forward to seeing a final version of your manuscript when it is ready. If you have any questions please do not hesitate to contact me.
------------------Edited abstract SUMO conjugation is known to occur in response to double-stranded DNA breaks in mammalian cells, but the role -if any-of SUMO deconjugation remains unclear. Here, we show the SUMO/Sentrin/Smt3-specific peptidase, SENP7, interacts with the chromatin repressive KRAB associated protein 1 (KAP1) through heterochromatin protein 1 alpha (HP1α). SENP7 promotes the removal of SUMO2/3 from KAP1 and regulates the interaction of the chromatin remodeler CHD3 with chromatin. Consequently, in the presence of CHD3, SENP7 is required for chromatin relaxation in response to DNA damage, for homologous recombination repair and cellular resistance to DNA damaging agents. Thus, deSUMOylation by SENP7 is required to promote a permissive chromatin environment for DNA repair.
Correspondence -authors' response 28 July 2013
Many thanks to you and reviewer 1 for looking at this once more. I can see that we haven't helped by making aspects of our study difficult to understand. We will incorporate your suggestions into the final version to improve its readability. The edited abstract reads just fine.
Many thanks -I hope to get back to you with the revision in the near future.
2nd Revision -authors' response 13 August 2013
Many thanks for your reply. In the submission that accompanies this letter we have undertaken the corrections you suggested (please see below for more details).
I look forward to your reply.
-----------Authors' reply to editor's comments:
We have moved the model and explained it in greater detail
In addition, please modify Fig. 1F to show each channel independently and show more cells in Fig  S1I. RPA figure channels split and additional images shown.
It would also be good to cite the JCB study on p400 facilitating Rad51 repair, and in the introduction mention that there are two other families of SUMO proteases (it now reads like only SENPS cleave SUMO)-incidentally both published in EMBO reports last year, studies which seems appropriate to cite. done I have also realized that the materials and methods section is extremely succinct. It is EMBO reports policy that basic Materials and Methods required for understanding the experiments performed must remain in the main text, although additional detailed information may be included as Supplementary Material. M&M now moved to the main text.
Shortening to accommodate all of these changes may be made easier by combining the Results and Discussion into a single section, which we require, and which will help eliminate the redundancy that is inevitable when discussing the same experiments twice. Now combined.
Also, if necessary, I could potentially increase the length to a maximum of 34,000 characters, given that four figures instead of five.
Statement given
Finally, we now encourage the publication of original source data -particularly for electrophoretic gels and blots, but also for graphs-with the aim of making primary data more accessible and transparent to the reader. If you agree, you would need to provide one PDF file per figure that contains the original, uncropped and unprocessed scans of all or key gels used in the figures and an Excel sheet or similar with the data behind the graphs. The files should be labeled with the appropriate figure/panel number, and the gels should have molecular weight markers; further annotation could be useful but is not essential. The source files will be published online with the article as supplementary "Source Data" files and should be uploaded when you submit your final version. If you have any questions regarding this please let us know. We have chosen, for time reasons not to undertake this -although we are very happy to submit all data if required.
4th Editorial Decision 13 August 2013
Thank you for the submission of the revised version of your study to EMBO reports. I am very pleased to accept your manuscript for publication in the next available issue of EMBO reports. Thank you for your contribution to our journal.
As part of the EMBO publication's Transparent Editorial Process, EMBO reports publishes online a Review Process File to accompany accepted manuscripts. As you are aware, this File will be published in conjunction with your paper and will include the referee reports, your point-by-point response and all pertinent correspondence relating to the manuscript.
If you do NOT want this File to be published, please inform the editorial office within 2 days, if you have not done so already, otherwise the File will be published by default [contact: emboreports@embo.org]. If you do opt out, the Review Process File link will point to the following statement: "No Review Process File is available with this article, as the authors have chosen not to make the review process public in this case."
Thank you again for your contribution to EMBO reports and congratulations on a successful publication. Please consider us again in the future for your most exciting work.
